Literature DB >> 29629797

Comparison of Performance Characteristics of American College of Radiology TI-RADS, Korean Society of Thyroid Radiology TIRADS, and American Thyroid Association Guidelines.

William D Middleton1, Sharlene A Teefey1, Carl C Reading2, Jill E Langer3, Michael D Beland4, Margaret M Szabunio5, Terry S Desser6.   

Abstract

OBJECTIVE: The American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) provides guidelines to practitioners who interpret sonographic examinations of thyroid nodules. The purpose of this study is to compare the ACR TI-RADS system with two other well-established guidelines.
MATERIALS AND METHODS: The ACR TI-RADS, the Korean Society of Thyroid Radiology (KSThR) Thyroid Imaging Reporting and Data System (TIRADS), and the American Thyroid Association guidelines were compared using 3422 thyroid nodules for which pathologic findings were available. The composition, echogenicity, margins, echogenic foci, and size of the nodules were assessed to determine whether a recommendation would be made for fine-needle aspiration or follow-up sonography when each system was used. The biopsy yield of malignant findings, the yield of follow-up, and the percentage of malignant and benign nodules that would be biopsied were determined for all nodules and for nodules 1 cm or larger.
RESULTS: The percentage of nodules that could not be classified was 0%, 3.9%, and 13.9% for the ACR TI-RADS, KSThR TIRADS, and ATA guidelines, respectively. The biopsy yield of malignancy was 14.2%, 10.2%, and 10.0% for nodules assessed by the ACR TI-RADS, KSThR TIRADS, and ATA guidelines, respectively. The percentage of malignant nodules that were biopsied was 68.2%, 78.7%, and 75.9% for the ACR TI-RADS, the KSThR TIRADS, and the ATA guidelines, respectively, whereas the percentage of malignant nodules that would be either biopsied or followed was 89.2% for the ACR TI-RADS. The percentage of benign nodules that would be biopsied was 47.1%, 79.7%, and 78.1% for the ACR TI-RADS, the KSThR TIRADS, and the ATA guidelines, respectively. The percentage of benign nodules that would be either biopsied or followed was 65.2% for the ACR TI-RADS.
CONCLUSION: The ACR TI-RADS performs well when compared with other well-established guidelines.

Entities:  

Keywords:  TI-RADS; thyroid cancer; thyroid guidelines; thyroid nodules; thyroid ultrasound

Mesh:

Year:  2018        PMID: 29629797     DOI: 10.2214/AJR.17.18822

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  37 in total

1.  Clinical practice guidelines on ultrasound-guided fine needle aspiration biopsy of thyroid nodules: a critical appraisal using AGREE II.

Authors:  Salvatore Gitto; Sotirios Bisdas; Ilaria Emili; Luca Nicosia; Lorenzo Carlo Pescatori; Kunwar Bhatia; Ravi K Lingam; Francesco Sardanelli; Luca Maria Sconfienza; Giovanni Mauri
Journal:  Endocrine       Date:  2019-03-22       Impact factor: 3.633

2.  Comparison and preliminary discussion of the reasons for the differences in diagnostic performance and unnecessary FNA biopsies between the ACR TIRADS and 2015 ATA guidelines.

Authors:  Xiao-Li Wu; Jia-Rui Du; Hui Wang; Chun-Xiang Jin; Guo-Qing Sui; Dong-Yan Yang; Yuan-Qiang Lin; Qiang Luo; Ping Fu; He-Qun Li; Deng-Ke Teng
Journal:  Endocrine       Date:  2019-03-04       Impact factor: 3.633

3.  Comparison among TIRADS (ACR TI-RADS and KWAK- TI-RADS) and 2015 ATA Guidelines in the diagnostic efficiency of thyroid nodules.

Authors:  Luying Gao; Xuehua Xi; Yuxin Jiang; Xiao Yang; Ying Wang; Shenling Zhu; Xingjian Lai; Xiaoyan Zhang; Ruina Zhao; Bo Zhang
Journal:  Endocrine       Date:  2019-01-18       Impact factor: 3.633

4.  A Multidisciplinary Head-to-Head Comparison of American College of Radiology Thyroid Imaging and Reporting Data System and American Thyroid Association Ultrasound Risk Stratification Systems.

Authors:  Bernice L Huang; Susana A Ebner; Jasnit S Makkar; Stuart Bentley-Hibbert; Robert J McConnell; James A Lee; Elizabeth M Hecht; Jennifer H Kuo
Journal:  Oncologist       Date:  2019-11-19

5.  Validation and comparison of three newly-released Thyroid Imaging Reporting and Data Systems for cancer risk determination.

Authors:  Ting Xu; Ya Wu; Run-Xin Wu; Yu-Zhi Zhang; Jing-Yu Gu; Xin-Hua Ye; Wei Tang; Shu-Hang Xu; Chao Liu; Xiao-Hong Wu
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

6.  Investigating the Effect of Thyroid Nodule Location on the Risk of Thyroid Cancer.

Authors:  Sina Jasim; Thomas J Baranski; Sharlene A Teefey; William D Middleton
Journal:  Thyroid       Date:  2020-01-28       Impact factor: 6.568

7.  Thyroid imaging reporting and data system (TIRADS) for ultrasound features of nodules: multicentric retrospective study in China.

Authors:  JianQiao Zhou; YanYan Song; WeiWei Zhan; Xi Wei; Sheng Zhang; RuiFang Zhang; Ying Gu; Xia Chen; Liying Shi; XiaoMao Luo; LiChun Yang; QiaoYing Li; BaoYan Bai; XinHua Ye; Hong Zhai; Hua Zhang; XiaoHong Jia; YiJie Dong; JingWen Zhang; ZhiFang Yang; HuiTing Zhang; Yi Zheng; WenWen Xu; LiMei Lai; LiXue Yin
Journal:  Endocrine       Date:  2020-08-27       Impact factor: 3.633

8.  Guidelines Are Not Gospel!

Authors:  Gilbert H Daniels; Peter A Kopp
Journal:  Thyroid       Date:  2019-06       Impact factor: 6.568

9.  Qualitative analysis of contrast-enhanced ultrasound in the diagnosis of small, TR3-5 benign and malignant thyroid nodules measuring ≤1 cm.

Authors:  Xin Li; Feng Gao; Fan Li; Xiao-Xia Han; Si-Hui Shao; Ming-Hua Yao; Chun-Xiao Li; Jun Zheng; Rong Wu; Lian-Fang Du
Journal:  Br J Radiol       Date:  2020-04-09       Impact factor: 3.039

10.  Diagnostic performance of US-based FNAB criteria of the 2020 Chinese guideline for malignant thyroid nodules: comparison with the 2017 American College of Radiology guideline, the 2015 American Thyroid Association guideline, and the 2016 Korean Thyroid Association guideline.

Authors:  Hui Zhu; Yan Yang; Senmin Wu; Kai Chen; Hongxia Luo; Jianle Huang
Journal:  Quant Imaging Med Surg       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.